News >

Frontline Venetoclax Shows Promise in Elderly AML Patients

Jason Harris
Published: Wednesday, Feb 07, 2018

Dr Courtney D. DiNardo
Courtney D. DiNardo, MD
Venetoclax (Venclexta) in combination with a hypomethylating agent induced complete remissions in 61% of patients aged 65 years or older with previously untreated acute myeloid leukemia (AML), according to phase Ib study data published in The Lancet Oncology.1

“What do these results mean for the treatment of acute myeloid leukemia? Initially, more patients should be treated with the hypomethylating agent–venetoclax combination, and these trials are ongoing,” wrote Müller-Tidow and Schlenk. “The preliminary data provided by DiNardo and colleagues suggests that the combination of hypomethylating drugs and venetoclax is effective in acute myeloid leukemia therapy. The magnitude of the benefit should be assessed in further clinical trials, but venetoclax is emerging as a novel and important drug in treatment of this disease.”


  1. DiNardo CD, Pratz KW, Letai A, et a. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study [published online January 12, 2018]. Lancet Oncol. 2018; 19:216-228. doi: 10.1016/S1470-2045(18)30010-X.
  2. Müller-Tidow C, Schlenk RF. A new option for remission induction in acute myeloid leukaemia [published online January 12, 2018]. Lancet Oncol. 2018; 19:156-157. doi: 10.1016/S1470-2045(18)30012-3.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication